Abstract: Manipulating autophagy is a promising strategy for treating cancer as several autophagy inhibitors are shown to induce autophagic cell death. One of these, autophagonizer (APZ), induces apoptosis-independent cell death by binding an unknown target via an unknown mechanism. To identify APZ targets, we used a label-free drug affinity responsive target stability (DARTS) approach with a liquid chromatography/tandem mass spectrometry (LC-MS/MS) readout. Of 35 protein interactors, we identified Hsp70 as a key target protein of unmodified APZ in autophagy. Either APZ treatment or Hsp70 inhibition attenuates integrity of lysosomes, which leads to autophagic cell death exhibiting an excellent synergism with a clinical drug, temozolomide, in vitro, in vivo, and orthotropic glioma xenograft model. These findings demonstrate the potential of APZ to induce autophagic cell death and its development to combinational chemotherapeutic agent for glioma treatment. Collectively, our study demonstrated that APZ, a new autophagy inhibitor, can be used as a potent antitumor drug candidate to get over unassailable glioma and revealed a novel function of Hsp70 in lysosomal integrity regulation of autophagy.
Introduction
Autophagic cell death is a type of apoptosis-independent cell death without chromatin condensation. It is accompanied by bulk-scale autophagic vacuolization, autophagosomes formation leading to fusion with lysosomes to form autolysosomes in the cytoplasm [1, 2] . Therefore, the maintenance of intact lysosomal integrity is pivotal to degrade the cellular components through sequential events of autophagy. Autophagy plays a crucial role in modulating cancer cellular homeostasis [3] . Targeting autophagy in cancer has provided opportunities for drug development [4, 5] , but autophagy modulation in cancer either promotes tumor suppression or survival according to specific autophagy pathways [6] . Hence, understanding these differences and the exact biological mechanism of autophagy is of fundamental and therapeutic importance. Recent studies identified a number of inhibitory small molecules of autophagy that effectively target cancer [7] [8] [9] , demonstrating the potential value of these compounds for cancer therapeutics. This strategy has been a focus of anticancer drug research, yet few candidates have shown this property or developed it as effective anticancer compounds.
Previously, we identified a novel autophagy regulator autophagonizer (APZ) that induces autophagosome (AP)-like vesicles and induces apoptosis-independent cancer cell death [10] ; therefore, by inducing autophagic cell death through large-scale autophagic vacuolization, APZ has potential for development as a novel autophagy inhibitor for anticancer therapy. Our previous study demonstrated that APZ induces large-scale accumulation of autophagosomes in the cytoplasm and triggers apoptosis-independent autophagic cell death. However, the cellular targets of APZ and the mechanism by which it mediates autophagic cell death remain unknown. Clarification of these issues will provide new routes and targets for cancer therapy.
To explore the molecular mechanism underlying the autophagy-regulating activity of APZ, DARTS and LC-MS/MS analysis were applied to identify the target proteins of APZ in its native form without chemical modification. We recently presented potent effectiveness for the label-free target identification method, DARTS and LC-MS/MS, by determining protein target and validating its biological relevancy of clinically well-known immunosuppressive drug, FK506, as a new autophagy flux inducer by binding V-ATPase [11] . In this study, the DARTS and LC-MS/MS method was expansively applied to identify a biologically relevant protein target of target unknown small molecule, APZ, and investigated its potential as a new anticancer agent. Herein, we report that APZ antagonizes Hsp70, inducing lysosomal dysfunction, inhibiting autophagic flux, which is called to impaired autophagy that might be caused by inhibiting lysosomal integrity, and ultimately leading to cell death in cancer cells and tumors. Notably, we reveal a novel function of Hsp70 in autophagy in the step of lysosome integrity into autophagosome. Collectively, APZ is a new small molecule for inducing autophagic cell death with potential as an anticancer agent for glioma treatment.
Results

Autophagonizer Functions Not by Inducing Autophagy, but by Inhibiting Autophagy
APZ was recently discovered as an autophagy regulator by a phenotype-based small molecule screen [10] . APZ induces autophagy-dependent cell death in various cancer cell lines, including HeLa and HT1080. However, the mechanism responsible for its biological activity remained unknown. To explore the underlying mechanism of APZ in autophagy-dependent cell death, we first investigated autophagy in cells treated with APZ by transmission electron microscopy (TEM) ( Figure 1A) . Notably, APZ-treated cells exhibited significant accumulation of autophagic vesicles, particularly autophagosomes containing multiple double-membrane structures (red arrows). In contrast, rapamycin, a well-known autophagy inducer, resulted in a smaller number of these structures and many more autolysosomes containing single-membrane and multilamellar structures (black arrows), indicating a different mode of action of APZ from that of rapamycin. Next, the effect of APZ on autophagic flux was investigated using double fluorescent-tagged chain protein type 3 (LC3) (mRFP/mCherry-GFP) to visualize autophagic flux based on the differing pH stabilities of GFP and mRFP. GFP confers weak stability and is degraded in acidic environments, such as lysosomes and autolysosomes. Therefore, if green/red (yellow) fluorescence accumulates in intracellular compartments, incomplete autophagy occurs through disruption of lysosome integrity or fusion of autophagosomes with lysosomes. Unexpectedly, APZ treatment resulted in yellow fluorescence accumulation, indicative of autophagosomes, leading to incomplete autophagy ( Figure 1B ). In contrast, rapamycin treatment induced red fluorescence accumulation in HeLa cells. Thus, APZ inhibits rather than induces autophagy, resulting in abnormal, impaired autophagy.
P62 is a protein expressed in late macro-autophagy and degraded in response to increasing autophagic flux, allowing its use to assess this flux [12] . As shown in Figure 1C , p62 levels increased for 48 h after APZ treatment, whereas the levels decreased from 24-48 h after rapamycin treatment. In addition, the levels of essential early markers for autophagosome formation, Atg5 and Atg16L [13] , were dose-dependently reduced by APZ treatment, whereas p62 and the lipid conjugated form of LC3 (LC3-II) gradually accumulated ( Figure S1 ). Hence, unlike rapamycin, APZ inhibits autophagic flux suggesting it promotes nonapoptotic cell death by the induction of autophagic cell death. In addition, the levels of essential early markers for autophagosome formation, Atg5 and Atg16L [13] , were dose-dependently reduced by APZ treatment, whereas p62 and the lipid conjugated form of LC3 (LC3-II) gradually accumulated ( Figure S1 ). Hence, unlike rapamycin, APZ inhibits autophagic flux suggesting it promotes nonapoptotic cell death by the induction of autophagic cell death. 
APZ Induces Autophagic Cell Death in Cancer Cell Lines
In the previous study, we showed that APZ treatment induces apoptosis-independent cell death in several cancer cell lines for 24 h [10] . Artesunate [14] (ART) induces apoptosis with characteristic by activating PARP (Poly (ADP-ribose) polymerase) cleavages [15] . Here, we investigated further whether APZ induces apoptosis after a long period of treatment from 24-72 h, because autophagy process can precede G2/M cell cycle arrest and apoptosis intervenes later to trigger apoptotic cell death [16] . Notably, APZ neither induced PARP cleavage (Figure 2A ) nor induced apoptosis. The effect of various inhibitors on cell death induced by APZ treatment was also investigated. The inhibitors of cell death Z-VAD-FMK (apoptosis inhibitor, 50 μM), necrostatin-1 (necrosis inhibitor, 10 μM), and liproxstatin-1 (ferroptosis inhibitor, 100 nM) was pretreated for 1 h and then APZ (10 μM) was treated for 24 h. Interestingly, the percentage of nonviable cells was not decreased in APZ-treated cultures ( Figure 2B ), implying that APZ induced autophagic cell death independent from apoptosis, necrosis, and ferroptosis, as well. To further elucidate the type of cell death induced by APZ, ATP levels were measured upon APZ treatment. APZ treatment gradually reduced ATP levels in the cells from as early as 5 min to 24 h, similar to rapamycin, which inhibits glycolysis to generate ATP [17] 
In the previous study, we showed that APZ treatment induces apoptosis-independent cell death in several cancer cell lines for 24 h [10] . Artesunate [14] (ART) induces apoptosis with characteristic by activating PARP (Poly (ADP-ribose) polymerase) cleavages [15] . Here, we investigated further whether APZ induces apoptosis after a long period of treatment from 24-72 h, because autophagy process can precede G2/M cell cycle arrest and apoptosis intervenes later to trigger apoptotic cell death [16] . Notably, APZ neither induced PARP cleavage (Figure 2A ) nor induced apoptosis. The effect of various inhibitors on cell death induced by APZ treatment was also investigated. The inhibitors of cell death Z-VAD-FMK (apoptosis inhibitor, 50 µM), necrostatin-1 (necrosis inhibitor, 10 µM), and liproxstatin-1 (ferroptosis inhibitor, 100 nM) was pretreated for 1 h and then APZ (10 µM) was treated for 24 h. Interestingly, the percentage of nonviable cells was not decreased in APZ-treated cultures ( Figure 2B ), implying that APZ induced autophagic cell death independent from apoptosis, necrosis, and ferroptosis, as well. To further elucidate the type of cell death induced by APZ, ATP levels were measured upon APZ treatment. APZ treatment gradually reduced ATP levels in the cells from as early as 5 min to 24 h, similar to rapamycin, which inhibits glycolysis to generate ATP [17] Cancers 2020, 12, 543 4 of 23 ( Figure 2C ). In normal cell lines, including Chang and HEK293 cells, treatment with APZ for 48 h showed differential sensitivity in cell proliferation and mitochondrial activity assays ( Figure 2D ). Cell proliferation remained greater than 50% at 48 h in normal cell lines even with a high dose of APZ (10 µM), whereas HeLa and other cancer cell lines exhibited IC 50 values below 5 µM. Hence, cancer cell lines (HeLa, U87MG) are more sensitive to APZ than those of normal cell lines probably due to activation of autophagy-induced cell death by APZ.
Cancers 2020, 12, 543 4 of 23 ( Figure 2C ). In normal cell lines, including Chang and HEK293 cells, treatment with APZ for 48 h showed differential sensitivity in cell proliferation and mitochondrial activity assays ( Figure 2D ). Cell proliferation remained greater than 50% at 48 h in normal cell lines even with a high dose of APZ (10 μM), whereas HeLa and other cancer cell lines exhibited IC50 values below 5 μM. Hence, cancer cell lines (HeLa, U87MG) are more sensitive to APZ than those of normal cell lines probably due to activation of autophagy-induced cell death by APZ. The glioblastoma cell line U87MG was also sensitive to APZ in vitro as determined by the MTT assay ( Figure 2D ). Therefore, these cells were used in a glioblastoma mouse xenograft model ( Figure  S2A ). Notably, APZ exhibited antitumor activity by decreasing tumor volume (vehicle-treated group: 1547 mm 3 [100%], APZ-treated group: 702 mm 3 [45%], 18 days) with no toxicity towards mice over the 18-days treatment. Acridine orange staining of APZ-treated xenograft tumors ( Figure S2B ) revealed that the red fluorescence indicative of lysosomal integrity was significantly reduced by APZ treatment. These results demonstrated that APZ could inhibit lysosomal integrity and proteolysis, which lead to impaired autophagy resulting in autophagic cell death of xenograft tumors. The glioblastoma cell line U87MG was also sensitive to APZ in vitro as determined by the MTT assay ( Figure 2D ). Therefore, these cells were used in a glioblastoma mouse xenograft model ( Figure  S2A ). Notably, APZ exhibited antitumor activity by decreasing tumor volume (vehicle-treated group: 1547 mm 3 [100%], APZ-treated group: 702 mm 3 [45%], 18 days) with no toxicity towards mice over the 18-days treatment. Acridine orange staining of APZ-treated xenograft tumors ( Figure S2B ) revealed that the red fluorescence indicative of lysosomal integrity was significantly reduced by APZ treatment. These results demonstrated that APZ could inhibit lysosomal integrity and proteolysis, which lead to impaired autophagy resulting in autophagic cell death of xenograft tumors. The low sensitivity to chemotherapeutic agent temozolomide (TMZ) of U87MG cells in vitro has been considered as one of the poor prognosis of patients despite of the addition of TMZ to radiation [18] . Therefore, there has been urgent demand for the development of adjuvant or synergic agent with TMZ. Cell proliferation of U87MG cells was inhibited by APZ treatment with IC 50 values below 5 µM, whereas TMZ did not exhibit the remarkable anticancer effect at 72 h even with a high dose of 300 µM ( Figure S3A ). Interestingly, however, APZ exhibited significant synergism with TMZ over 72 h ( Figure  S3B ) validating from the combination index (CI) method [19] . In this analysis, a value of <1 indicates synergism and the lowest CI value for APZ in combinational effect with TMZ in U87MG was 0.35 ( Figure S3C ). To further investigate the effectiveness and the safety of APZ as a chemotherapeutic agent in vivo, a mouse orthotopic glioma model was used by intracranial injecting GFP-GL261 mouse glioma cells into congenic B6 wild type mice. GL216 glioma was known to exhibit the malignant characteristics in high-grade glioma [20, 21] .
Similar to effectiveness in U87MG, cell proliferation of GFP-GL261 cells was also inhibited by APZ treatment with IC 50 values below 5 µM ( Figure 3A ) and exhibited significant synergism in combinational effect with TMZ in GFP-GL261 at 72 h ( Figure 3B ). Next, we evaluated tumor progression bearing orthotropic glioma derived from GFP-GL261 ( Figure 3C ). APZ alone treatment over the 18-days treatment had reduced implanted tumor volume such as TMZ alone treatment (vehicle-treated group: 39 mm 3 ). To analyze combinational effect of APZ with TMZ, CI value was calculated in an orthotropic glioma model. CI value for APZ in combinational effect with TMZ for antitumor effect in orthotropic glioma derived from GFP-GL261 was 0.49. Collectively, these results demonstrate that APZ exhibits significant synergism with TMZ both in vitro and in vivo. To investigate whether APZ inhibits autophagic flux in vivo as well, p62 and LC3B puncta were stained in these agents-treated group ( Figure 3D ). Immunofluorescent analysis demonstrated that both APZ alone treatment and combinational treatment of TMZ with APZ increased the accumulation of p62 and LC3-II in the brain glioma tissues compared with the vehicle or TMZ alone treated group. Additionally, combinational treatment of TMZ with APZ significantly recovered vessel abnormality by inhibiting vascular invasion from brain to glioblastoma region ( Figure S4 ). These results demonstrate that APZ can be used as a potent therapeutic drug candidate to get over unassailable brain cancer. 
DARTS and LC-MS/MS Analysis for Identification of APZ Protein Targets
DARTS is a label-free method for target identification of bioactive small molecules that exploits changes in protein proteolytic susceptibility [22] . To identify the protein targets of APZ, we developed a new method combining DARTS with liquid chromatography/tandem mass spectrometry (DARTS and LC-MS/MS) that improves the labor-intensiveness of traditional affinity-based methods. In this new combined method, the small molecule is exposed to the cell lysate, a proteome pool, to allow small molecule-protein target interactions. The stability of the target protein then increases, rendering it to be resistant to pronase treatment because of conformational changes induced by tight binding of the small molecule. Proteins with no or weak binding affinity with the small molecule are degraded, and proteins with high affinity binding resist protease treatment are identified by LC-MS/MS analysis.
Our DARTS and LC-MS/MS method consists of five major steps and is summarized in the schematic diagram shown in Figure 4A : (1) Exposure of the small molecule to proteins in the cell lysate proteome pool, to allow for small molecule-protein target interactions, (2) pronase digestion of proteins unprotected by the small molecule, where proteins that bind resist protease treatment while proteins with little or no binding to the small molecule are degraded ( Figure S5A ), (3) further proteolysis with trypsin and LC-MS/MS analysis of resulting peptides to determine sequence coverage, (4) identification of proteins protected by the small molecule based on its enhanced sequence coverage by more than 3% compared to controls [23] , and (5) selection of likely protein targets based on candidates with phenotypic relevancy to the small molecule [24, 25] .
Thirty-five candidate protein targets showed reasonable sequence coverage values that increased significantly upon APZ treatment compared to controls in the absence of APZ, as shown by heatmap analysis ( Figure 4B , Table 1 ). High protein sequence coverage means higher confidence in interactors than proteins with low sequence coverage values. This enables interpretation of diverse transition patterns of sequence coverage with pronase. To select the protein target of APZ, sequence-based peptide analysis on DARTS and LC-MS/MS information was applied. As shown in Figure 1 , we demonstrated that APZ inhibited autophagic flux. Inhibition of autophagic flux has been reported to be mainly caused by lysosomal stability, integrity, and functionality [26] [27] [28] [29] . Among 35 candidate protein targets, Hsp70 modulates lysosomal integrity and chaperone function, and thus this protein was selected as a key binding protein of APZ and applied for sequence-based peptide analysis. Recovery of sequence coverage at specific locations reveals binding specificity and candidate binding sites between a small molecule and cognate protein target sequences. Sequence coverage analysis revealed that specific peptide fragments in the nucleotide binding domain (NBD, ATPase domain) of Hsp70 were protected by APZ in the pronase-treated proteome ( Figure 4C ). Since the NBD of Hsp70 is reportedly essential to its molecular function as a chaperone and protein interactions with cochaperones [30, 31] , we focused on this domain as a specific binding region of Hsp70 for APZ. Additionally, we analyzed seven peptides of pronase nontreated control sample detected in DARTS and LC-MS/MS proteome analysis as shown in Figure 4C ,D. Seven peptides were stabilized by APZ treatment more than 10 % compared to pronase alone treatment ( Figure S5B ). Six of these peptides belong to NBD and one was a helical lid domain. Notably, two peptides of NBD ( 1 and 3 of Figure 4D ) were not detected by MS/MS in the absence of APZ after treatment with pronase. Interestingly, K71, G339, and R342 in stabilized peptides by APZ treatment were included in the NBD of Hsp70. However, 6 stabilized peptide by APZ treatment showed mild increase (17%) of its quantification without the significant difference compared to pronase alone treatment, suggesting that APZ may interact this peptide as a transient or weak binding. Therefore, K71 in 1 stabilized peptide is most likely a tightly interacting amino acid residue of Hsp70 with APZ as shown in Figure 4E (red circle). This result also demonstrated that K71 plays significant roles for the direct binding of APZ to the NBD of Hsp70. In silico docking showed that APZ could directly bind to the NBD of Hsp70 ( Figure 4E ). Many charged ion groups and nonpolar rings of APZ can also contribute to its binding of the NBD in the same manner as ATP ( Figure S5C ) and VER-155008 ( Figure S5D ), a known Hsp70 inhibitor. In addition, these two ligands also shared a key binding amino acid of Hsp70, K71, in 1 stabilized peptide of the NBD of Hsp70 by APZ treatment. A label-free DARTS and LC-MS/MS method was applied to identify the protein target of APZ. First, a DARTS assay with pronase digestion was applied for three groups: (1) Control, (2) pronase-alone treated, (3) pronase treated with APZ in duplicate. Second, LC-MS/MS analysis of the proteome protected by the small molecule followed by protein searching based on peptides using the IP2 database were conducted. Finally, 35 protein target candidates were selected with reasonable sequence coverage values (pronase alone < pronase treated with APZ < control). Filtering based on function by known phenotype narrowed down functional targets. Rescue of sequence coverage in A label-free DARTS and LC-MS/MS method was applied to identify the protein target of APZ. First, a DARTS assay with pronase digestion was applied for three groups: (1) Control, (2) pronase-alone treated, (3) pronase treated with APZ in duplicate. Second, LC-MS/MS analysis of the proteome protected by the small molecule followed by protein searching based on peptides using the IP2 database were conducted. Finally, 35 protein target candidates were selected with reasonable sequence coverage values (pronase alone < pronase treated with APZ < control). Filtering based on function by known phenotype narrowed down functional targets. Rescue of sequence coverage in specific domain suggests binding specificity and a possible binding site. Certain domains were protected. The chemical properties of APZ facilitate ionic charge interaction, noncovalent, and hydrogen bond formation via interactions between D10, K71, K271, and R272, which are common amino acids interacting with APZ, ATP, and VER-155008 in NBD, with high binding affinity (CDOCKER energy of ATP: −54.18 kcal/mol; VER-155008: −22.95 kcal/mol; APZ: −21.68 kcal/mol). Especially, charge interaction between amide group of APZ and aspartic acids (D10, D199, D206) of inner pocket in NBD of Hsp70 can play significant roles in the potent and high affinity binding of APZ to the NBD of Hsp70. These results also demonstrate that combined DARTS and LC-MS/MS-based target identification is an effective platform for identifying novel cellular protein targets of untagged small molecules.
Characterization of Hsp70 as a Potential Protein Target of APZ
The DARTS assay with Western analysis alone could be also used to validate the LC-MS/MS results by demonstrating the increased stability of Hsp70 after APZ treatment even after treatment with pronase for up to 20 min, whereas β-actin, a protein with no APZ binding affinity, was significantly digested by pronase ( Figure 5A) . Notably, the stability of Hsp70 was increased in a dose-dependent manner by APZ treatment, suggesting that APZ tightly interacts with Hsp70 ( Figure 5B ). Despite evidence suggesting that Hsp70 stabilizes lysosomal integrity by binding to endolysosomal anionic phospholipids [32] , the mechanism by which Hsp70 affects autophagy has not been demonstrated so far. Our results indicated that APZ inhibits Hsp70 interaction or function on lysosomal integrity in autophagosomes by binding Hsp70. 
Validation of Hsp70 as a Protein Target of APZ
To validate the biological relevance of Hsp70 on autophagy, we explored the effects of Hsp70 knockdown on autophagy. As shown by immunoblotting for LC3-II, a component of the 
To validate the biological relevance of Hsp70 on autophagy, we explored the effects of Hsp70 knockdown on autophagy. As shown by immunoblotting for LC3-II, a component of the autophagosome membrane, and other autophagic marker, p62 [33] , Hsp70 knockdown mimicked the same activities at the p62 and LC3-II levels as did APZ treatment ( Figure 6A, Figure S1 ). Furthermore, APZ treatment of Hsp70-knockdown cells resulted in higher LC3-II expression than that observed following APZ treatment alone ( Figure 6B) . Thus, APZ's mode of action involves Hsp70 inhibition, as LC3-II induction by APZ increased greatly upon Hsp70 knockdown. In contrast, rapamycin-induced autophagy was unaffected by Hsp70 knockdown ( Figure 6B) .
PES, a known Hsp70 inhibitor that also binds its substrate-binding domain (SBD) and induces lysosomal dysfunction [34, 35] exhibited similar biological activities as APZ on LC3-II levels with and without E64D (Figure 6C,D) . Furthermore, PES and Hsp70 knockdown inhibited autophagy flux, similar to APZ treatment ( Figure 6E ). Hsp70 was overexpressed using an EGFP-Hsp70 clone using wildtype (WT) Hsp70 and a form with a mutation in the ATP-binding motif, Hsp70 K71E [36] ( Figure S6B ). Overexpression of WT Hsp70 rescued the cell growth inhibition caused by APZ both in cancer (HeLa) and normal cell (Chang) lines, but overexpression of mutant-type (MT) Hsp70 did not ( Figure 6F , Figure S6C ). Moreover, the lysosome inhibitory activity caused by APZ treatment was rescued by overexpressing WT Hsp70, but not by overexpressing MT Hsp70. Notably, neither WT nor MT Hsp70 rescued lysosome inhibition caused by bafilomycin A treatment, a well-known V-ATPase inhibitor of lysosomes [37] (Figure 6G) . These results clearly demonstrate that Hsp70 is a biologically relevant protein target of APZ responsible for its autophagy-inhibiting mechanism.
To further investigate whether APZ shows on-target effects in normal and cancer cell lines, the expression level of Hsp70 was examined in four cell lines (Chang, HEK293: Normal cell lines; HeLa, U87MG: Cancer cell lines) to establish a correlation between APZ and its potential target.
Protein Hsp70 ( Figure 7A ). As a result, the expression level of Hsp70 in normal cells was higher than that of cancer cells, which is consistent with results in Figure 6 . Then, IC 50 values, which was monitored in cell proliferation assay with four cell lines ( Figure 2D ), were calculated. Pearson correlation coefficient was used to validate the relationship between Hsp70 expression and APZ efficacy on cell proliferation. Notably, there is a significantly positive correlation (r = 0.94) between the expression level of Hsp70 and the IC 50 of APZ ( Figure 7B ). In addition, the effects of APZ on autophagy degrading markers, p62 and LC3-II kinetics, in normal cell lines were examined to assess autophagic flux. APZ treatment rapidly increased the levels of p62 and LC3-II in 24 h and then decreased at 48 h both in Chang ( Figure 7C ) and HEK293 ( Figure 7D ) cell lines, indicating the degradation of the proteins at the late stage of autophagy. For further validation, a double-tagged LC3 (mRFP-GFP) plasmid was transfected in Chang, HEK293, and U87MG cell lines. Notably, APZ treatment resulted in increase in red fluorescence (autolysosomes) in Chang and HEK293 cells indicating autophagy flux, whereas resulted in increase in yellow fluorescence (autophagosomes) in U87MG cells ( Figure 7E ) indicative of autophagy inhibition. These results demonstrated that the efficacy of APZ depends on its target protein, Hsp70. 6F, Figure S6C) . Moreover, the lysosome inhibitory activity caused by APZ treatment was rescued by overexpressing WT Hsp70, but not by overexpressing MT Hsp70. Notably, neither WT nor MT Hsp70 rescued lysosome inhibition caused by bafilomycin A treatment, a well-known V-ATPase inhibitor of lysosomes [37] (Figure 6G) . These results clearly demonstrate that Hsp70 is a biologically relevant protein target of APZ responsible for its autophagy-inhibiting mechanism. 
APZ Inhibits Lysosomal Integrity by Antagonizing Hsp70
An accumulation in cellular cargo proteins can be caused at any step after autophagosome formation and can be induced either by inhibiting fusion of autophagosomes with lysosomes or losing the ability for lysosomal proteolysis. Therefore, we explored whether impaired autophagy induced by APZ and Hsp70 inhibition might be caused by interrupting fusion between both compartments. Examination of the LC3-marking autophagosomes and LAMP1-labeled lysosomes in 
An accumulation in cellular cargo proteins can be caused at any step after autophagosome formation and can be induced either by inhibiting fusion of autophagosomes with lysosomes or losing the ability for lysosomal proteolysis. Therefore, we explored whether impaired autophagy induced by APZ and Hsp70 inhibition might be caused by interrupting fusion between both compartments. Examination of the LC3-marking autophagosomes and LAMP1-labeled lysosomes in response to Hsp70 inhibition including Hsp70 knockdown and inhibitors (APZ, PES) suggested that Hsp70 inhibition did not decrease the colocalization of LC3 and LAMP1-labeled lysosomes similar to rapamycin known as a fusion inducer ( Figure 8A ). Thus, Hsp70 inhibition does not compromise or delay the fusion of autophagosomes with lysosomes. An impaired autophagosomal clearance after APZ treatment led us to assess whether lysosomal integrity was affected by APZ. APZ treatment reduced lysosomal integrity for 12-24 h. Moreover, Hsp70-deficient cells exhibited the same reduction in lysosomal integrity from 6 h, whereas rapamycin treatment significantly increased acridine orange intensity, indicating that rapamycin induces autophagic flux by activating lysosome activity ( Figure 8B ). Thus, both inhibition of Hsp70 by APZ and its genetic knockdown inhibit lysosomal integrity.
To investigate the effect of APZ on lysosomal integrity and enzyme activity, the lysosomal enzyme cathepsin D [38] was examined in HeLa cells after treatment with APZ and rapamycin ( Figure 8C ). APZ treatment reduced the levels of the mature form of cathepsin D in a time-dependent manner, whereas rapamycin did not; rather, it induced the mature form of cathepsin D as demonstrated by acridine orange staining of lysosomes ( Figure 8B ). Thus, APZ inhibits lysosomal integrity by antagonizing Hsp70. LAMP2 protein levels reflect the size and number of lysosomal compartments [39] , providing a correlation between lysosomal integrity and APZ. Upon treatment with APZ and Hsp70 knockdown, LAMP2 levels significantly decreased compared to those in untreated or rapamycin-treated cells ( Figure 8D,E) , demonstrating that APZ inhibits lysosomal integrity by binding Hsp70. Additionally, cathepsin D (CTSD) with four agents-treated brain glioma sections ( Figure 3C,D) , were stained to validate whether APZ inhibits lysosomal integrity leading to autophagic cell death in the orthotropic xenograft model ( Figure 8F ). Staining of tumor tissues for CTSD showed a diffuse pattern in the vehicleor TMZ alone-treated group, whereas the significantly reduced levels were observed in APZ alone-or cotreatment of APZ with TMZ group. These results suggest that Hsp70 regulates the activities affected by APZ, such as lysosomal formation, autophagic flux, and autophagic cell death, and that the NBD of Hsp70 is required for this regulation. 
APZ treatment
led us to assess whether lysosomal integrity was affected by APZ. APZ treatment reduced lysosomal integrity for 12-24 h. Moreover, Hsp70-deficient cells exhibited the same reduction in lysosomal integrity from 6 h, whereas rapamycin treatment significantly increased acridine orange intensity, indicating that rapamycin induces autophagic flux by activating lysosome activity (Figure 8B). Thus, both inhibition of Hsp70 by APZ and its genetic knockdown inhibit lysosomal integrity.
Discussion
Autophagy inhibitors that induce autophagic cell death have great potential as valuable new anticancer therapeutics [40] , but the precise autophagy mechanism has been established for surprisingly few anticancer drugs. As a recent case, compound CA-5f was identified as a novel late stage autophagy inhibitor by interrupting fusion between autophagosomes and lysosomes [41] . CA-5f exhibited selective cytotoxicity against A549 nonsmall cell lung cancer (NSCLC), which is a resistant cancer cell to radiation or chemotherapy, than normal human umbilical vein endothelial cells (HUVECs) by inhibiting autophagic flux without affecting lysosomal functionality. This study presented that discovering novel autophagy inhibitors could be one of the promising strategies for clinical application and recent advances in cancer. Although few autophagy inhibitors targeting cancer have been developed, discovering new autophagy inhibitors can reveal new autophagy mechanisms and so provide new routes for the development of new cancer-targeting agents.
The unique features of APZ as a new Hsp70 inhibitor come from its physicochemical structure and properties distinct from those of known Hsp70 inhibitors leading to high hydrophobic property (LogP: 4.9) and tight binding to nucleotide binding domain (NBD) of Hsp70. APZ binds with Hsp70 through hydrophobic interaction mainly, which is pivotal for formation of rigid complex and tight binding [42] . For example, VER-155008 has been reported to competitively bind to ATP in NBD and inhibits ATPase and chaperon activity by binding tightly with NBD leading to cell death [43] . In these studies, APZ induced apoptosis-independent and cancer specific cell death without affecting the growth of normal cell lines or mice and the effects of both compounds were rescued by genetic overexpression of wildtype Hsp70. Notably, APZ exhibited significant synergism with temozolomide, a chemotherapeutic drug of glioblastoma, in vitro and orthotropic mouse model. Treatment of malignant glioblastoma has remained a challenge because it requires complete elimination of the residual tumor, which leads to fatal recurrence, and blood-brain barrier (BBB) blocks delivery of anticancer drugs. Therefore, potent drugs complementing these limitations must be developed. APZ shows the remarkable anticancer effects through the significant synergism with the existing drug of TMZ both in subcutaneous and orthotopic tumor mouse models.
Our in silico docking studies of three ligands including ATP, APZ, and VER-155008 induced a strong interaction with NBD through a similar binding motif. The tight binding property of APZ with Hsp70 can contribute its cancer cell specific cell death activity and provide a tool compound to explore Hsp70 as a new molecular probe for Hsp70 distinct from currently known Hsp70 inhibitors such as PES, VER-155008, and apoptozole [44] . We propose that APZ is a new molecular probe that selectively targets cancer as a new Hsp70 inhibitor and is a unique tool for basic studies of autophagy and cell death mechanisms. Collectively, APZ can be used as a new molecular probe to elucidate new roles of Hsp70 with its unknown functions including autophagosomes formation, and lysosome blocker with autophagosomes that might provide the new biological and mechanistic insights on Hsp70 in future studies.
We found that regulation of Hsp70 expression by both transient knockdown and overexpression specifically affected the biological activities of APZ. These results are consistent with VER-155008, which has been reported to rescue the inhibition of cell proliferation when Hsp70 was transiently overexpressed whereas the biological effects was potentiated by cotreatment with Hsp90 inhibitor [45] . Thus, our results highlight Hsp70 as a promising therapeutic target for cancer treatment. Selective inhibition of cell proliferation in cancer cells over normal cells and the ability of APZ to suppress xenograft tumors suggest the potential of APZ as an anticancer therapeutic. In agreement with our proposed model, treatment of APZ to a glioblastoma mouse xenograft model resulted in significant suppression of lysosome function.
Materials and Methods
Compounds and Antibodies
APZ was screened from among 2000 chemicals obtained from the structure-based synthetic and natural product libraries of ChemDiv, Chemgenex, and Korea Chemical Bank. All compounds were stored as stock solutions in 10 mM DMSO at −20 • C and diluted with Dulbecco's Modified Eagle Medium (DMEM) before in vitro experiments. The working solution was freshly prepared in a basal medium, and the control group was treated with the same amount of DMSO as a vehicle control. Bafilomycin A1, rapamycin, dithiothreitol (DTT), trifluoperazine, iodoacetamide (IAA), formic acid, E64D cysteine protease inhibitor, pifithrin-µ (PES), and artesunate (ART) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Pronase and protease inhibitor cocktail tablets were obtained from Roche (Basel, Switzerland). Phosphatase inhibitor solution and Triton X-100 were purchased from Sigma-Aldrich. Hoechst 33342, Lipofectamine LTX, Lipofectamine 2000, DMEM, RPMI, MEM, and fetal bovine serum (FBS) were purchased from Invitrogen (Carlsbad, CA, USA). Antilight chain 3 (LC3) antibody was purchased from MBL (Nagoya, Japan). Anti-ATG16L1 antibodies was purchased from Cell Signaling Technology (Danvers, MA, USA), and antiHsp70, anticathepsin D (CTSD), antiLAMP2, antiPARP, and antiβ-actin antibodies were purchased from Abcam (Cambridge, UK). Coomassie blue and silver staining dye were purchased Thermo Fisher Scientific (Waltham, MA, USA). mRFP-GFP-LC3B plasmids were gifts from Dr. Jaewhan Song at Yonsei University (Seoul, Korea).
Cell Culture
HeLa (human cervical cancer), A549 (human lung carcinoma), HEK293 (human embryonic kidney), Chang (human liver), and EGFP-LC3 stably expressing COS7 (monkey kidney) cells were grown in DMEM containing 10% FBS and 1% antibiotics. U87MG (human glioblastoma) cells were grown in a minimum essential medium eagle (MEM) containing 10% FBS and 1% antibiotics. All cell cultures were maintained at pH 7.4 in a humidified incubator at 37 • C under 5% CO 2 in air. 
In Silico Docking Study
All molecular docking analyses were performed with Discovery Studio 2016 software (Accelrys, San Diego, CA, USA) adopting the CHARMm force field. The crystal structure of the human Hsp70 nucleotide-binding domain (PDB ID 3ATV) was obtained from the RCSB protein data bank. The protein structures of the Hsp70 nucleotide-binding domain were energy-minimized using the Powell algorithm. The ligands were docked using Ligandfit. The Ligandfit parameters were validated using the ligand from the Hsp70 nucleotide-binding domain crystal structure. APZ was docked to the ATPase domain of the protein, and nine poses were generated. The most predictive binding modes were determined based on various scoring functions (Ligscore1_Dreiding, Ligscore2_Dreiding, PLP1, PLP2, PMF, DOCK_SCORE), and binding energies were calculated in Ligandfit.
Immunoblotting
Soluble proteins were harvested from cells by using a SDS lysis buffer (50 mM Tris HCl at pH 6.8 containing 10% glycerol, 2% SDS, 10 mM dithiothreitol, and 0.005% bromophenol blue). Equal volumes of proteins were separated by 8% or 12.5% SDS-PAGE and transferred to polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). Blots were then blocked and immunolabeled overnight at 4 • C with primary antibodies, antiLC3 (MBL), PARP, p-mTOR, mTOR, p-S6K, S6K, Atg16L1 (Cell Signaling Technology), p62 (BD Biosciences, Franklin Lakes, NJ, USA), GFP, Hsp70, Cathepsin D, LAMP2, and actin (Abcam). Immunolabeling was visualized using an enhanced chemiluminescence kit (Amersham Life Science, Inc., Amersham, UK) according to the manufacturer's instructions. Images were quantified using Image Lab (Bio-Rad, Hercules, CA, USA). Actin was used as an internal control.
Immunocytochemistry Staining
To determine the effect on the fusion between autophagosomes and lysosomes, HeLa cells were seeded at a density of 1.5 × 10 5 cells/well in 6-well plates and incubated overnight. Following incubation overnight, the cells samples were fixed with 4% paraformaldehyde and washed with PBS three times. Then, the cells were treated with compounds or si-Hsp70 for the time periods indicated, followed by treatment with LC3 and LAMP1 primary antibodies (Abcam, Cambridge, UK) for 1 h. Nuclei were stained with DAPI. Images were obtained using a confocal microscope at a 400× magnification.
ATP-Monitoring Luminescence Assay
To determine the effect of cellular ATP levels on cell proliferation, an ATPlite 1-step Luminescence Assay Kit (Perkin Elmer, Waltham, MA, USA) was purchased and used according to the manufacturer's instruction. HeLa cells were seeded in 96-well white plates at 2000 cells/well and incubated overnight. After drug treatments, luminescence was measured using a Victor 3 Multilabel Plate Reader (Perkin Elmer).
Cell Proliferation Assay
All cells were seeded in 96-well plates at 3000 cells/well and incubated overnight. Drugs were added to the cells to determine their effects on cell proliferation. Cells were grown for 48 h, and growth was analyzed by the 3-(4,5-dimehylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma-Aldrich) colorimetric assay. MTT-formazan in each well was dissolved in 150 µL DMSO, and the absorbance at 540 nm was read with a microplate reader.
Cell Death Assay
HeLa cells were seeded at 1 × 10 4 cells/well in a 12-well plate and incubated overnight at 37 • C. One hour before treatment with APZ, inhibitors of cell death including Z-VAD-FMK, necrostatin-1, and liproxstatin-1 were added. After 24 h, cell viability was determined by trypan blue staining.
Transmission Electron Microscopy
Cells were harvested by trypsinization, washed twice with phosphate-buffered saline (PBS), and fixed with 2% paraformaldehyde/2% glutaraldehyde in a 0.1 M phosphate buffer at pH 7.4. After fixation, the cells were washed with sodium cacodylate, scraped from the plates, and pelleted by centrifugation. Cell pellets were post-fixed with 1% (v/v) osmic acid in sodium cacodylate and stained with 1% uranyl acetate. After dehydration, the pellets were embedded in Durcopan (Sigma-Aldrich).
Ultrathin sections were prepared using an LKB 8800 Ultratome III and observed with a Philips EM 400T transmission electron microscope.
DARTS Assay
Cell lysates were obtained from HeLa cells. Cells were scraped and lysed with a M-PER lysis buffer. After centrifugation for 15 min at 10,000× g, the supernatant was obtained, and protein content was quantified using the Bradford reagent. Before drug treatment, protein concentration was diluted to 1 mg/mL. Samples were treated with the drugs APZ and DMSO for 4 h at 4 • C. Samples were then incubated with pronase or distilled water, as indicated, for 2, 10, and 20 min at 25 • C. A small portion of each sample was used for Western blot analysis, and the remainder of each sample was frozen for use in the LC−MS/MS analysis. Actin was used as an internal control.
In Vivo Mouse Tumor Xenograft Assay
Mice were housed in a pathogen-free facility at the Laboratory Animal Research Center of Yonsei University (Seoul, Korea). These mice were handled in accordance with the Institutional Animal Care and Use Committee (permission number: IACUC-201511-527-01) and International Guidelines for the Ethical Use of Animals. For intracranial tumor models, 2 × 10 5 GL261-GFP were implanted into the right hemispheres of 8-10-wk-old male experimental mice via stereotaxic injection. After 1 week, mice were randomly selected and separated into four groups (four mice per group) and intraperitoneally treated with vehicle or TMZ (25 mg/kg) or APZ (10 mg/kg) or combinational treatment (TMZ 25 mg/kg, APZ 10 mg/kg) every two days for 18 days. Tumor volume was calculated according to the formula 0.5 × A × B2, where A is the longest diameter of a tumor, and B is its perpendicular diameter. For subcutaneous tumor models, U87 glioblastoma cells (5 × 10 6 cells) suspended in 200 µL PBS/Matrigel (1:1) were subcutaneously implanted into the dorsal flank of athymic nude mice (four-week-old female BALB/c nu/nu; Orient Bio, Seoul, Korea). Once the tumors became palpable (50-100 mm 3 , 10 days), mice were randomly selected and separated into two groups (five mice per group) and intraperitoneally treated with vehicle or APZ (10 mg/kg) every two days. Vehicle and drugs were dissolved in a saline:Ethanol:Tween 80 solution at a ratio of 88:2:18. The tumor volume and mouse body weight were measured daily using the following formula: π/6 × length × width × height. After 1 h of drug treatment, mice were sacrificed, and tissue samples were obtained. The tumors were surgically removed and slowly frozen with dry ice (−70 • C).
Acridine Orange Staining
HeLa cells were seeded at a density of 1.5 × 10 5 cells/well in 6-well plates and incubated overnight. The cells were treated with drugs for the time periods indicated, followed by treatment with 2 µg/mL acridine orange (Sigma-Aldrich). For tissue staining, sequential frozen sections were cut from each tumor. Vehicle-and APZ-treated sections were stained with 5 µg/mL acridine orange. Nuclei were stained with DAPI. Following incubation for 20 min, the cells and tissue samples were fixed with 4% paraformaldehyde and washed with PBS three times. Images were obtained using a confocal microscope at a 400× magnification. Red fluorescence intensity was quantified using Image J (NIH, Bethesda, MD, USA).
mRFP-GFP-LC3B Plasmid Transfection
All cells were seeded in 6-well plates at 1.5 × 10 5 cells/well and incubated overnight. All cells were transfected with negative control or mRFP-GFP-LC3B plasmids using Lipofectamine LTX transfection reagent (Invitrogen) for 4 h. The cells were treated with drugs for the time periods indicated, followed by treatment with mRFP-GFP-LC3B plasmid (1000 ng). Nuclei were stained with DAPI. Following incubation for 20 min, the cells and tissue samples were fixed with 4% paraformaldehyde and washed with PBS three times. Images were obtained using a confocal microscope at a 400× magnification.
Statistical Analysis
All data are expressed as the means ± SEM with GraphPad Prism (ver. 5.00 for Windows; GraphPad Software, Inc., San Diego, CA, USA). Data were obtained from at least three independent experiments. Statistical analyses were performed using an unpaired, two-tailed Student's t-test. P-values less than 0.05 were considered statistically significant (* indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001).
Conclusions
Here, our findings demonstrated that the DARTS and LC-MS/MS method is a powerful strategy for the discovery of novel targets with the significant advantage over traditional affinity based approaches in that unmodified compounds can be profiled, so considerably speeding up discovery. The present study revealed how to interpret combined analysis results to filter perturbations that were likely relevant to the observed phenotype of APZ. We found that filtering based on function to a known phenotype of small molecule is a useful method for narrowing down functional targets. Importantly, the DARTS and LC-MS/MS method effectively circumvents the chemical modification and coupling to solid supports required by conventional strategies and is a simple and accessible method.
Collectively, our study showed that both APZ treatment and orthogonal Hsp70 inhibition increased specific markers of autophagy to form autophagosomes. In addition to the role of APZ as a specific inhibitor of Hsp70, we also revealed a new functional role of Hsp70 in autophagosome formation and induction of incomplete lysosomes leading to autophagic cell death in cancer cells. Moreover, we established the exact mechanisms of the functional role of Hsp70 to provide a further insight that can target cancer effectively. This novel role of Hsp70 likely involves the stabilization of lysosomes based on pH integrity and suggests a mechanism for its action. 
